GSE193900 GSE193905 PURA knockdown HeLa 1 v 0 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE193900_GSE193905_PURA knockdown_HeLa_1_v_0_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE193900_GSE193905_PURA knockdown_HeLa_1_v_0_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE193900_GSE193905_PURA knockdown_HeLa_1_v_0_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE193900_GSE193905_PURA knockdown_HeLa_1_v_0_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

mitochondrial ribosomal protein S18B

Gene

GOLGA2 pseudogene 7

Gene

GTP binding protein 6

Gene

multidrug resistance-related protein

Gene

small nucleolar RNA host gene 15

Gene

leukocyte receptor cluster member 9

Gene

long intergenic non-protein coding RNA 1963

Gene

HLA complex group 18

Gene

CTA-216E10.6

Gene

long intergenic non-protein coding RNA 1128

  • Gene

    mitochondrial ribosomal protein S18B


  • Gene

    GOLGA2 pseudogene 7


  • Gene

    GTP binding protein 6


  • Gene

    multidrug resistance-related protein


  • Gene

    small nucleolar RNA host gene 15


  • Gene

    leukocyte receptor cluster member 9


  • Gene

    long intergenic non-protein coding RNA 1963


  • Gene

    HLA complex group 18



  • Gene

    long intergenic non-protein coding RNA 1128

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.